Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-01

Study Completion Date

2028-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Study of Fetal Neurotransplantation for the Treatment of Parkinson's Disease

NCT00004844

Parkinson Disease

UNKNOWN NA

A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease

NCT05635409

Parkinson Disease

ACTIVE_NOT_RECRUITING PHASE1

Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease

NCT06236230

Parkinson Disease

RECRUITING PHASE4

Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease

NCT06821529

Parkinson Disease

NOT_YET_RECRUITING PHASE1

Double-blind Placebo Surgery Trial for Treatment of Parkinson's Disease

NCT03347955

Parkinson Disease Surgery

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Single-center, open-label, uncontrolled. The primary objective of this study is to evaluate the safety of CT1-DAP001 in subjects with Parkinson's disease by determining the incidence and severity of adverse events, especially graft expansion, after transplantation into the corpus striatum. Other objectives are to evaluate the efficacy of CT1-DAP001 through the assessment of Parkinson's disease symptoms and clinical severity or progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PD - Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This study will be conducted as a single-center, open-label, uncontrolled study to evaluate the safety of transplantation of CT1-DAP001 as the primary objective, and as a secondary objective, to evaluate efficacy. Seven (7) subjects with PD will be followed up for 24 months after transplantation of approximately 4.2-5.4 × 106 dopaminergic progenitors per side into the bilateral putamen.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single-center, open-label, uncontrolled

To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease

Group Type OTHER

Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)

Intervention Type COMBINATION_PRODUCT

Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.

Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)

Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.

Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain.

Intervention Type COMBINATION_PRODUCT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Investigational imaging - FDOPA & FEPPA Investigational device - Sunovion needle

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject has a diagnosis of PD (clinically established or clinically probable) in accordance with the MDS Clinical Diagnostic Criteria for Parkinson's Disease (2015).
2. The subject has an inadequate response to drug treatments.
3. The subject is ≥ 40 years and ≤ 75 years of age at the time of informed consent.
4. The subject has had PD for at least 5 years.
5. The subject has both ON and OFF (as demonstrated by the MDS-UPDRS Part III and a symptom diary).
6. The subject does not have a debilitating dyskinesia score greater than or equal to 3 on the MDS-UPDRS.
7. The subject is in stage 2 or higher on the Hoehn and Yahr scale at OFF time.
8. The subject is in stage 3 or lower on the Hoehn and Yahr scale at ON time.
9. The subject has an L-dopa response of 30% or more without influence of antiparkinsonian drugs.
10. The subject has the following organ functions as determined by laboratory tests at Screening visit:

1. Neutrophil count ≥ 2,000/μL
2. Platelet count ≥ 5.0 × 104/μL
3. AST, ALT ≤ 3.0 × upper limit of normal
4. Total bilirubin ≤ 1.5 × upper limit of normal
5. eGFR ≥ 60 mL/min/1.73 m2 (As part of Creatinine testing, an estimated glomerular filtration rate (mL/min/1.73 m2)will be calculated based on the CKD-EPI 2021 equation)
11. The subject is willing to avoid pregnancy using abstinence, highly effective means of birth control, surgical sterility, or menopause.
12. The subject is willing to comply with the protocol-required assessments.
13. The subject provides written informed consent to participate in the study. If the subject cannot sign due to physical constraints, verbal consent may be provided with signature of a Legally Authorized Representative.

Exclusion Criteria

1. The subject has an abnormal brain MRI suggestive of brain pathology other than Parkinson's disease.
2. Atypical parkinsonism (Parkinsonism-Plus syndrome, secondary parkinsonism, hereditary parkinsonism).
3. The subject has clinical indication or diagnosis of abnormal immune function.
4. The subject has been diagnosed with a major neurocognitive disorder such as dementia, or is high risk for this.
5. The subject has bleeding tendency or abnormal coagulation function as evidenced by platelets \<50 or PT/PTT \> 1.5x normal.
6. The subject is HBs antigen-positive, or HBs antibody- or HBc antibody-positive with evidence of HBV-DNA.
7. The subject is anti-HIV antibody positive.
8. The subject is anti-HTLV-1 antibody-positive.
9. The subject has active infection such as hepatitis C or syphilis (STS/TPHA).
10. The subject has hypersensitivity or contraindication to tacrolimus, concomitant drugs (e.g., levodopa, carbidopa, MRI contrast), and/or their components.
11. Contraindications to general anesthesia as evaluated by subject matter experts.
12. The subject has a serious allergy to a component (e.g., gentamicin, component of bovine origin, or component of porcine origin) used in the preparation of the study product.
13. The subject has any of the following conditions/diseases concurrently:

1. Malignant neoplasm
2. Epilepsy
3. Psychiatric disease (e.g., uncontrolled anxiety or depression, bipolar disorder, schizophrenia)
4. Diabetes mellitus with poorly controlled blood glucose (glycosylated hemoglobin \> 9.0%, or fasting plasma glucose (FPG) ≥ 200 mg/dL (11.1 mmol/L).
5. Other serious concurrent diseases (e.g., cerebrovascular disorder, heart disease, chronic respiratory disease, inadequately controlled hypertension) as determined by the investigator.
14. The subject has a history of any of the following:

1. Prior malignancy \< 5 years prior to Screening. Patients who had prior malignancies within 5 years and in complete remission with expected survival of more than 5 years are not excluded
2. Epilepsy
3. Cerebral hemorrhage or stroke
4. Psychiatric disease (e.g., uncontrolled anxiety or depression, bipolar disorder, schizophrenia)
5. Congenital long QT syndrome
6. Pallidotomy, thalamotomy, or Deep Brain Stimulation
15. The subject is pregnant or lactating or does not agree to avoid pregnancy throughout the study.
16. The subject has undergone transplantation of human iPSC-derived dopaminergic progenitors.
17. The subject, in the opinion of the investigator or sub investigator, is not appropriate to conduct the study safely.

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No